Kanger International has clinched a deal with Sparmak Medical Equipment Trading LLC, an authorised partner of G42 Medications Trading LLC to distribute Sinopharm’s COVID-19 testing solutions using the revolutionary OXLAMP technology in Malaysia
Under the agreement, Kanger will make an initial purchase of 1,000,000 COVID-19 testing solutions and corresponding diagnostic devices using the OXLAMP technology, with deliveries expected to commence as soon as November this year.
The Oxlamp testing method is widely used in China and is easy to set up and does not need expensive equipment. Testing can be carried out on-site on a wide scale with results made available within 30 minutes. According to Kanger it has targeted the tourism sector as an attractive market potential followed by other public spaces like airports, train stations, and hotels where they can carry out wide and rapid testing. Currently, travelers leaving and returning to Malaysia would need to conduct a polymerase chain reaction (“PCR”) test of which results can take up to 3 days to be made available. The testing devices are web-enabled which will allow for results to be immediately uploaded to the relevant health apps and portals for easy and quick verification.
Beyond that, this method is also suitable to be used at workplaces with a large number of employees such as factories, construction sites, and shopping malls. The market potential is attractive.
The testing solution has achieved the highly acclaimed CE certification and has also been approved by the Ministry of Health & Prevention of United Arab Emirates (UAE) as well as the EU Ministry of Health Welfare and Sports.
Kanger has yet to receive authorisation from the Medical Device Authorisation as well as relevant approvals from regulatory authorities prior to distribution.
The revolutionary OXLAMP technology was developed at Oxford University and utilises a simple viral ribonucleic acid (“RNA”) testing method, loop-mediated isothermal amplification (“RT-LAMP”) to detect fragments of the virus without professional instruments or training. The test is done through a nasal swab collection with samples analysed at the point of collection enabling speedy results delivery.
The COVID-19 Oxlamp testing solutions to be procured by Kanger are produced by Shanghai GeneSC Biotech Co., Ltd. a subsidiary of China National Pharmaceutical Group Co., Ltd. The Oxlamp technique is already being used across mainland China, with GeneSC having the exclusive license for distribution in China.
